Lenalidomide maintenance treatment demonstrates significant overall survival benefit following HDT-ASCT

Meta-analysis of results from three randomised control trials has demonstrated that maintenance treatment with lenalidomide (Revlimid®) following high-dose therapy and autologous stem cell transplantation (HDT-ASCT) in newly diagnosed myeloma patients has a significant overall survival (OS) benefit. Published in the Journal of Clinical Oncology, the results of this meta-analysis, which used data pooled from the…

Details

Supportive treatments

The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies. Sakellari I et al. Clin Lymphoma Myeloma Leuk. 2017 Jun 29. pii: S2152-2650(17)30096-4. doi: 10.1016/j.clml.2017.06.008. [Epub ahead of print]. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Multiple Myeloma. Ghosh N et al. Biol Blood Marrow…

Details

Related conditions

Congestive Heart Failure with Preserved Ejection Fraction in a Patient with Light Chain (AL) Amyloidosis and Multiple Myeloma. Carrizales-Sepúlveda EF et al. Am J Case Rep. 2017 Jul 13;18:790-793. Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. Meziane I et al. Haematologica. 2017 Jul 4. pii: haematol.2017.171108. doi: 10.3324/haematol.2017.171108. [Epub ahead of print]. Monoclonal Gammopathy…

Details

General

Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods. Ramsenthaler C et al. Qual Life Res. 2017 Jul 27. doi: 10.1007/s11136-017-1660-z. [Epub ahead of print]. The Experience of Myeloma Caregivers During Home-Based Oral Chemotherapy Treatment: A Qualitative Study. Morris M et al. Semin Oncol Nurs. 2017 Jul 24. pii: S0749-2081(17)30045-1. doi: 10.1016/j.soncn.2017.05.010. [Epub ahead…

Details

Emerging treatments

CAR-Ts move beyond B-cell cancers to myeloma. Dolgin E. Nat Biotechnol. 2017 Jul 12;35(7):599-601. doi: 10.1038/nbt0717-599. The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Brayer J et al. Ther Adv Hematol. 2017 Jul;8(7):209-220. doi: 10.1177/2040620717710171. Epub 2017 Jun 28. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation…

Details

Diagnostic techniques and prognostic indicators

Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test. Heaney JLJ et al. BMC Nephrol. 2017 Jul 20;18(1):247. doi: 10.1186/s12882-017-0661-z. Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. van Beers EH et al. Clin Lymphoma Myeloma Leuk. 2017 Jul 4. pii: S2152-2650(17)30278-1. doi: 10.1016/j.clml.2017.06.020. [Epub…

Details

Current treatments

Efficacy and Safety of Bortezomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma: A Meta-Analysis. Sun CY et al. Biosci Rep. 2017 Jul 13. pii: BSR20170304. doi: 10.1042/BSR20170304. [Epub ahead of print]. Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma(TUBA study). Nakasone H et al. Hematol Oncol. 2017 Jul 6.…

Details